TL;DR
This study demonstrates that incorporating the plasma omega-6 to omega-3 fatty acid ratio (ω6:ω3) into the existing SCORE2 cardiovascular risk prediction model significantly improves its accuracy. This finding is crucial because it offers a potentially modifiable biomarker that can help refine risk stratification and guide personalized nutritional interventions for preventing major adverse cardiovascular events (MACE).
What Problem Does This Paper Address?
Cardiovascular disease (CVD) remains a leading cause of death globally. Accurate prediction of an individual's risk of experiencing a major cardiovascular event is essential for effective primary prevention strategies. While established risk prediction models like SCORE2 are valuable, they often leave a significant "residual risk" unaccounted for, even in individuals with optimally managed traditional risk factors. This gap highlights the need for novel biomarkers that can capture underlying pathological pathways not reflected by conventional factors. The authors focus on the plasma ω6:ω3 ratio, a marker of inflammatory balance, as a promising candidate to enhance risk stratification beyond current models.
Methods
The researchers utilized a large prospective cohort study from the UK Biobank (UKB). They employed nuclear magnetic resonance (NMR) spectroscopy to measure the plasma ω6:ω3 ratio. To evaluate the predictive performance of this new marker, they compared two models: the standard SCORE2 algorithm and an extended model that included the plasma ω6:ω3 ratio. The comparison was performed on an independent validation cohort using established metrics for model performance:
- Harrell's C-index: Measures the model's ability to discriminate between individuals who will and will not experience an event.
- Net Reclassification Improvement (NRI): Assesses how well the extended model reclassifies individuals into more accurate risk categories compared to the original model.
- Integrated Discrimination Improvement (IDI): Quantifies the improvement in the model's ability to discriminate between cases and controls.
They also assessed model calibration to ensure predicted risks align with observed outcomes and used decision curve analysis (DCA) to evaluate the clinical utility of the extended model.
Datasets
The study utilized data from the UK Biobank (UKB), a large prospective cohort study of over half a million individuals.
- Training Set: 70% of the UKB participants (N = 128,290) were used for model development.
- Validation Set: The remaining 30% of UKB participants (N = 54,940) were used for independent evaluation of the models.
The study did not introduce new benchmarks but rather evaluated the performance of an existing model (SCORE2) with the addition of a novel biomarker.
Key Insights and Ideas
- The ω6:ω3 Ratio as a Holistic Inflammatory Marker: The ω6:ω3 ratio is not just a measure of dietary intake but an integrated biomarker reflecting long-term dietary exposure and endogenous metabolism. It captures the balance between pro-inflammatory (ω6) and anti-inflammatory (ω3) lipid mediators, offering a more comprehensive view of metabolic health than individual fatty acids alone.
- Beyond Traditional Risk Factors: The study strongly suggests that the ω6:ω3 ratio provides prognostic information that is independent of established SCORE2 covariates (age, sex, smoking, blood pressure, cholesterol). This implies it can help identify individuals at risk who might be missed by current screening methods.
- Modifiable Target for Intervention: The fact that the ω6:ω3 ratio is a modifiable biomarker is a critical takeaway. This opens avenues for personalized nutritional interventions aimed at restoring a more favorable balance, potentially leading to better cardiovascular outcomes.
- Men Benefit More (Initially): The improvement in risk reclassification was more pronounced in men than in women, suggesting potential sex-specific differences in how this biomarker influences cardiovascular risk.
Key Results
- Improved Discrimination: Adding the plasma ω6:ω3 ratio to the SCORE2 model significantly increased the C-index in the validation set from 0.742 to 0.747 (p < 0.001).
- Enhanced Risk Reclassification: The extended model led to a statistically significant improvement in risk reclassification, with an NRI of 8.4% and an IDI of 0.021 for the total population.
- Dose-Response Relationship: A clear, monotonically increasing risk of MACE was observed with higher levels of the ω6:ω3 ratio, with no evidence of significant non-linearity.
- Men vs. Women: The improvement in risk stratification was more pronounced in men (NRI: 8.9%) compared to women (NRI: 5.6%), although the improvement in women was still statistically significant for IDI.
- Excellent Calibration: Both the original and extended models demonstrated excellent calibration, meaning predicted risks closely matched observed outcomes.
- Clinical Utility: Decision curve analysis indicated that the extended model provided a consistently higher net benefit than the SCORE2 model alone across a clinically relevant range of threshold probabilities.
Limitations and Future Work
- Observational Design: The study design is observational, meaning it demonstrates an association rather than definitive causality.
- Single Baseline Measurement: The analysis relied on a single baseline measurement of the ω6:ω3 ratio, which does not account for potential changes in diet or metabolic status over the follow-up period.
- Modest Magnitude of Improvement: While statistically significant, the magnitude of improvement in discrimination (ΔC-index = 0.005) is modest. The authors suggest that its primary clinical utility may lie in guiding personalized interventions rather than immediate algorithm calibration due to cost-effectiveness considerations.
- "Healthy Volunteer Bias": The UK Biobank cohort is known to have a "healthy volunteer bias," which may limit the generalizability of findings to more vulnerable populations.
- Plasma vs. Diet: The authors emphasize that the plasma ω6:ω3 ratio is an integrated biomarker reflecting both diet and metabolism, and should not be directly equated with dietary intake alone.
Future work could involve Mendelian randomization studies to explore causal relationships and investigate the impact of interventions aimed at modifying the ω6:ω3 ratio. Further research could also explore sex-specific mechanisms and the utility of this biomarker in different clinical settings, such as secondary prevention.
Summary updated